Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo SmithKline

This article was originally published in The Tan Sheet

Executive Summary

John Ziegler will assume the position of president, Consumer Healthcare, the same position he currently holds for SmithKline Beecham, and will report to Glaxo SmithKline CEO-designate Jean-Pierre Garnier under a corporate executive structure for the newly proposed merged entity announced Feb. 3. The heads of the firm's U.S. pharmaceutical operations will be George Morrow and David Stout, who hold the same positions at Glaxo Wellcome and SmithKline, respectively. They will report to Robert Ingram, who will take over as chief operating officer and president of Pharmaceutical Operations worldwide. The three could play a prominent role in determining a switch strategy; in announcing the proposed merger, company execs noted the switch potential of several Rx drugs, such as Relenza influenza treatment, Lotronex for irritable bowel syndrome and Flonase for allergic rhinitis (1"The Tan Sheet" Jan. 24, p. 3)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS090837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel